证券日报网讯2月4日，天宇股份（300702）在互动平台回答投资者提问时表示，公司目前生产经营一切 正常，在手订单充足，排产计划紧凑。2026年一季度及2025年经营数据，请以公司后续发布的定期报告 为准。如有达到披露标准的重大合同，公司将及时公告。持续提升高毛利制剂业务占比是公司的重要战 略方向，目前该业务发展势头良好。具体的占比数据受市场波动及项目进度影响，请关注公司后续披露 的定期报告。 ...

Core Viewpoint - The company has successfully completed the construction of a high-purity solvent project with an annual production capacity of 20,000 tons, which has effectively improved its capacity utilization rate [1] Group 1: Production and Capacity - The Changyi Tianyu project has officially commenced operations, leading to an increase in capacity utilization [1] - The company continues to solidify its position as a leading manufacturer of sartans, with a significant focus on the integration of raw materials and formulations [1] Group 2: Market Position and Revenue - The company's revenue from both raw materials and formulation products is showing a growth trend [1] - Several products have obtained CEP certification or are actively pursuing FDA certification, with revenue contributions expected to materialize as global market expansion progresses [1]

Q4单季度有所承压，预计主要由于阶段毛利率及费用影响。 #非沙 调整即机会，Q4阶段费用扰动不改拐点趋势，持续重点推荐【天宇股份】 #Q4阶段毛利率、费用扰动，不改长期趋势。 公司发布2025年归母净利润盈利1.2亿元~1.6亿元，同比增长114.53%~186.05%。 全年维度业绩大幅增长，拐点明确，得益于非沙坦及制剂业务快速增长。 Q4单季度有所承压，预计主要由于阶段毛利率及费用影响。 #非沙坦、制剂有望保持快速增长、盈利水平加速修复，25年初以来持续推荐，逐渐跑出α。 非沙坦业务项目丰富，随着专利悬崖，仿制药订单和原研转移订单有望快速增加，接续布局的十几个项目有望快 速放量；CDMO业务持续放量，制剂业务处于快速增长通道。 前期大量产能建设已进入收获期，利用率持续爬升将带来利润率持续修复。 未来2-3年有望持续超预期，空间可观。 #沙坦业务见底、盈利触底回升、主业空间可观，沙坦价格自2021年始，经历四年下行调整，近一两年内已逐步筑 牢底部，盈利有限，行业有望逐步出清，触底回升。 调整即机会，Q4阶段费用扰动不改拐点趋势，持续重点推荐【天宇股份】 #Q4阶段毛利率、费用扰动，不改长期趋势。 公司发布2 ...

南财智讯1月30日电，天宇股份发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 1.20亿元—1.60亿元，同比预增114.53%—186.05%；预计2025年全年归属于上市公司股东的扣除非经常 性损益的净利润为1.12亿元—1.52亿元，同比预增66.03%—125.32%。报告期内，公司业绩实现显著增 长，主要驱动因素包括：公司积极把握市场机遇，持续拓宽客户渠道并加强精细化管理，企业核心竞争 力得到进一步加强；主营业务拓展方面，通过优化产品结构、完善市场布局及加强成本管控等措施，有 效提升了公司非沙坦类业务及制剂业务的营收规模和毛利增长；公司通过大幅缩减外汇衍生品交易规模 有效降低损失。报告期内公司预计非经常性损益影响归属于上市公司的净利润金额约800万元，主要系 政府补助。 ...

天宇股份公告，预计2025年度净利润为1.2亿元–1.6亿元，同比增长114.53%-186.05%。报告期内，公司 业绩实现显著增长，主要驱动因素包括：公司积极把握市场机遇，持续拓宽客户渠道并加强精细化管 理，企业核心竞争力得到进一步加强；主营业务拓展方面，通过优化产品结构、完善市场布局及加强成 本管控等措施，有效提升了公司非沙坦类业务及制剂业务的营收规模和毛利增长；公司通过大幅缩减外 汇衍生品交易规模有效降低损失。 ...

Financial Projections - The estimated net profit for 2025 is projected to be between RMB 120 million and RMB 160 million, representing a year-on-year increase of 114.53% to 186.05% compared to RMB 55.93 million in the previous year[3] - The estimated net profit after deducting non-recurring gains and losses is projected to be between RMB 112 million and RMB 152 million, reflecting a year-on-year growth of 66.03% to 125.32% compared to RMB 67.46 million in the previous year[3] - The estimated impact of non-recurring gains and losses on the net profit attributable to shareholders is approximately RMB 8 million, primarily from government subsidies[6] - The performance forecast has not been audited by the accounting firm, and specific financial data will be disclosed in the 2025 annual report[7] Business Performance Drivers - The significant growth in performance is driven by the company's proactive market opportunities, expanded customer channels, and enhanced management efficiency[5] - The company has optimized its product structure and improved market layout, leading to increased revenue and gross profit in its non-sartan and formulation businesses[6] - The company has effectively reduced losses by significantly cutting back on foreign exchange derivative trading[6] Investor Guidance - The company emphasizes the importance of cautious decision-making and awareness of investment risks for investors[7]

Group 1 - The report indicates that the A-share market is experiencing a typical spring rally characterized by initial strength followed by stabilization and structural differentiation, with major indices recording positive returns as of January 28, 2026 [6] - The average daily trading volume in January reached 3.04 trillion yuan, an increase of 1.16 trillion yuan month-on-month, indicating a significant influx of new capital and a loose liquidity environment driving the index upward [2] - Regulatory measures, including raising the minimum margin requirement from 80% to 100%, have led to fluctuations in market sentiment and a deceleration in the index's upward momentum [3] Group 2 - The report highlights that technology assets are experiencing a rotation between thematic and cyclical investments, with thematic investments (e.g., commercial aerospace, AI applications) initially favored but cooling off due to increased margin requirements [4] - In the cyclical sector, non-ferrous metals, basic chemicals, and oil & petrochemicals have shown strong performance driven by three factors: demand from high-end manufacturing, proactive supply-side adjustments, and external geopolitical risks [4] - The report anticipates a structural market characterized by a focus on "resources + technology + overseas expansion," with low-risk preference assets potentially outperforming in certain phases [5] Group 3 - The investment strategy emphasizes focusing on "external demand cyclical + AI industry chain," highlighting the potential for global manufacturing recovery to support resource prices and opportunities for Chinese manufacturing to expand overseas [5] - The AI industry remains a clear investment theme, with a shift from thematic to performance-driven investments, particularly in areas with supply shortages such as power supply and semiconductor sectors [5] - The report recommends a selection of stocks across various sectors, including Invesco's Nonferrous ETF, Dongpeng Beverage, and Huazhong Precision, among others, reflecting a diversified investment approach [10]

每日经济新闻 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯，天宇股份1月26日晚间发布公告称，公司第五届第十八次董事会会议于2026年1月26日以 通讯方式召开。会议审议了《关于2026年度日常关联交易预计的议案》等文件。 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 （记者 曾健辉） ...

证券代码：300702 证券简称：天宇股份 公告编号：2026-006 浙江天宇药业股份有限公司 关于 2026 年度日常关联交易预计的公告 （二）2025 年度日常关联交易实际发生情况（未审计） 1 / 4 单位：万元 关联交易类别 关联人 关联交易 内容 关联交易定 价原则 2026 年预 计金额 截至披露日 已发生金额 上年发生 金额 向关联人采购 上海星可 及其子公 司 原材料 市场价格 6,000.00 298.83 1,921.22 向关联人销售 产品 市场价格 10,000.00 1,132.31 2,897.81 向关联人销售 九洲药业 及其子公 司 产品 市场价格 3,000.00 0 354.88 | 关联交易类别 | 关联人 | 关联交易 | 实际发生 | 预计金额 | 实际发生额 占同类业务 | 实际发生额 与预计金额 | 披露日期 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 内容 | 金额 | | | | 及索引 | | | | | | | | 比例（%） | 差异（%） | | | | 向关联人 ...

1、审议通过了《关于 2026 年度日常关联交易预计的议案》； 董事会认为：公司 2026 年度预计发生的日常关联交易事项，为公司业务发 展及生产经营的正常需要，交易价格以市场公允价格为基础，不存在损害公司和 股东利益的情形。公司不会因上述交易对关联方形成依赖，不会影响公司的独立 性。 证券代码：300702 证券简称：天宇股份 公告编号：2026-005 浙江天宇药业股份有限公司 第五届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 浙江天宇药业股份有限公司（以下简称"公司"）第五届董事会第十八次会 议于 2026 年 1 月 26 日 9：30 以通讯方式召开，本次会议通知于 2026 年 1 月 24 日以书面、电话、电子邮件方式送达。会议应出席董事 8 名，实际出席董事 8 名。会议由董事长屠勇军先生主持，公司高级管理人员列席了本次会议。本次董 事会会议的召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 与会董事就各项议案进行了审议、表决，形成决 ...